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LETTER TO THE EDITOR 
 
Hepatitis B virus (HBV) infection is a major public 
health problem affecting more than 250 million people 
globally. Chronic hepatitis B (CHB) is a result of an 
acute, unresolved infection, that, overtime, may lead to 
cirrhosis and its complications such as liver failure and 
hepatocellular carcinoma [1]. In the last 15 years, sever-
al inhibitors of HBV polymerase, namely nucleos(t)ide 
analogues (NAs), have been developed and introduced 
in clinical practice, allowing long term suppression of 
HBV replication (virological response) and alanine ami-
notransferase (ALT) normalization (biochemical re-
sponse) [2]. Hepatitis B surface antigen (HBsAg) loss 
and seroconversion to anti-HBs has been traditionally 
considered the final goal of antiviral treatment (func-
tional cure). However, a complete cure could be 
achieved only with the physical elimination of HBV co-
valently-closed-circular DNA (cccDNA) which acts as 
template for all viral transcriptions and is responsible 
for long lasting viral persistence [3]. Currently, novel 
approaches aiming at HBV cccDNA elimination or in-
activation are under evaluation at a preclinical level [3]. 
However, the possibility to measure intrahepatic HBV 
cccDNA is limited by liver biopsy availability and the 
lack of sensitive standardized PCR methods. 
Hepatitis B core-related antigen (HBcrAg) is a novel se-
rum biomarker combining the antigenic reactivity re-
sulting from hepatitis B e antigen (HBeAg), HBV core 
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antigen, and a 22 kDa core-related protein (p22cr) 
mainly found in HBV empty particles [4,5]. It has been 
reported that HBcrAg levels varied significantly among 
the four natural phases of HBV infection showing high 
predictive performance for distinguishing between 
HBeAg-negative inactive/quiescent carrier and HBeAg-
negative hepatitis-patients (area under the curve [AUC] 
= 0.931) and for the discrimination between immune 
tolerant and immune clearance phases (AUC = 0.704) 
[6]. 
Interestingly, a significant correlation between HBcrAg 
and intrahepatic HBV cccDNA has been reported [7-9]. 
Suzuki et al., investigating the correlation between 
HBcrAg and intrahepatic HBV cccDNA in a cohort of 
Japanese CHB patients, found a positive correlation be-
tween the two parameters (r = 0.692, p < 0.001). In ad-
dition, a significant correlation between HBcrAg and in-
trahepatic HBV cccDNA was also observed in patients 
that experienced HBsAg negativization (r = 0.482,         
p = 0.006), suggesting a potential role of HBcrAg also 
in subjects with occult HBV infection [7]. More recent-
ly, Matsuzaki et al. also reported a correlation between 
HBcrAg and HBV cccDNA levels (r = 0.616,                
p < 0.001) in patients undergoing liver transplant [8]. 
After excluding preoperative state samples from analy-
sis, HBcrAg remained significantly correlated to HBV 
cccDNA (r = 0.402, p = 0.046). Furthermore, HBcrAg 
and HBV cccDNA values showed similar kinetics dur-
ing pre- and post-transplantation, highlighting HBcrAg 
reliability as a surrogate biomarker for HBV cccDNA 
[8]. Finally, a large-scale study including 305 liver bi-
opsies and corresponding serum samples collected from 
138 NAs-treated patients pointed out a median HBcrAg 
reduction at ≥ 6 years of therapy comparable to the 
magnitude of HBV cccDNA decay [9]. HBcrAg was 
strongly correlated with intrahepatic HBV cccDNA        
(r = 0.70, p < 0.0001). According to HBeAg status, 
HBcrAg was significantly correlated to HBV cccDNA 
levels both in the 133 HBeAg-positive patients               
(r = 0.66, p < 0.0001) and in the 172 -negative patients 
(r = 0.45, p < 0.0001). Moreover, analyzing 130 sam-
ples of HBV DNA-negative patients receiving antiviral 
therapy, authors observed that HBcrAg was still detect-
able in 101 of them, being significantly correlated with 





Since the quantification of HBV cccDNA levels will be 
important in clinical trials evaluating novel treatment 
concepts to cure HBV infection, its relationship with 
HBcrAg quantification renders the latter a reliable non-
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